RedHill secures funding for Phase 2 study of COVID-19 treatment

seekingalpha2023-12-04

RedHill (NASDAQ:RDHL) said it has received new non-dilutive external funding for a Phase 2 study of its oral antiviral drug RHB-107 in the treatment of early COVID-19. The Israeli company said the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

beherenow
2023-12-05
beherenow
Keeping an eye on this.

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2388730643?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1332149063/image_1332149063.jpg","is_english":true,"pubTime":"2023-12-04 22:35","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2388730643","market":"us","top_or_hot":-1,"title":"RedHill secures funding for Phase 2 study of COVID-19 treatment","media":"seekingalpha","content":"<div>\n<p>RedHill (NASDAQ:RDHL) said it has received new non-dilutive external funding for a Phase 2 study of its oral antiviral drug RHB-107 in the treatment of early COVID-19. The Israeli company said the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4042841-redhill-secures-funding-for-phase-2-study-of-covid-19-treatment\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RedHill secures funding for Phase 2 study of COVID-19 treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRedHill secures funding for Phase 2 study of COVID-19 treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-12-04 22:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4042841-redhill-secures-funding-for-phase-2-study-of-covid-19-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>RedHill (NASDAQ:RDHL) said it has received new non-dilutive external funding for a Phase 2 study of its oral antiviral drug RHB-107 in the treatment of early COVID-19. The Israeli company said the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4042841-redhill-secures-funding-for-phase-2-study-of-covid-19-treatment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1066051498.USD","symbol_name":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","start_time":0,"source_url":"https://seekingalpha.com/news/4042841-redhill-secures-funding-for-phase-2-study-of-covid-19-treatment","article_id":"2388730643","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1332149063/image_1332149063.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2388730643","pubTimestamp":1701700558,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"RedHill  said it has received new non-dilutive external funding for a Phase 2 study of its oral antiviral drug RHB-107 in the treatment of early COVID-19. The Israeli company said the approximately $4.8M in funding will cover the entirety of the RHB-107 arm of the ACESO PROTECT study for early COVID-19 outpatient treatment. The study, which will have 300 patients, is expected to begin enrollment in the coming weeks and be completed by the end of 2024. If approved, the product could provide an additional option to Pfizer’s  Paxlovid in the early COVID-19 treatment space, RedHill said.   More on RedHill  RedHill stock nearly doubles in value pre-market on a five-year FDA exclusivity grant Financial information for RedHill","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","BK4548":"巴美列捷福持仓","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4592":"伊斯兰概念","SG9999001176.USD":"United Global Healthcare Acc USD","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4139":"生物科技","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4533":"AQR资本管理(全球第二大对冲基金)","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BK4007":"制药","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4535":"淡马锡持仓","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","BK4550":"红杉资本持仓","RDHL":"Redhill Biopharma Ltd","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4551":"寇图资本持仓","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","PFE":"辉瑞","BK4581":"高盛持仓","BNTX":"BioNTech SE"},"translate_title":"RedHill获得新冠肺炎治疗二期研究的资金","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BNTX":1,"RDHL":1,"PFE":1},"content_text":"RedHill (NASDAQ:RDHL) said it has received new non-dilutive external funding for a Phase 2 study of its oral antiviral drug RHB-107 in the treatment of early COVID-19. The Israeli company said the approximately $4.8M in funding will cover the entirety of the RHB-107 arm of the ACESO PROTECT study for early COVID-19 outpatient treatment. The study, which will have 300 patients, is expected to begin enrollment in the coming weeks and be completed by the end of 2024. If approved, the product could provide an additional option to Pfizer’s (PFE) Paxlovid in the early COVID-19 treatment space, RedHill said.   More on RedHill  RedHill stock nearly doubles in value pre-market on a five-year FDA exclusivity grant Financial information for RedHill","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":248518477795488,"gmtCreate":1701711493457,"gmtModify":1701711530720,"author":{"id":"4133911624467882","authorId":"4133911624467882","name":"beherenow","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Keeping an eye on this.&nbsp;","listText":"Keeping an eye on this.&nbsp;","text":"Keeping an eye on this.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/248518477795488","repostId":2388730643,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":1,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2388730643"}